Antimicrobial drugs and community-acquired methicillin-resistant Staphylococcus aureus, United Kingdom.

Emerging Infectious Diseases
Verena Schneider-LindnerSamy Suissa

Abstract

We report results of a case-control study of the association between receipt of antimicrobial agents and diagnosis of community-acquired methicillin-resistant Staphylococcus aureus (MRSA) in the United Kingdom. Eligible adults, selected from the General Practice Research Database, had no previous diagnosis of MRSA, no hospitalization in the past 2 years, and > or = 2 years of follow-up recorded in the database. For 2000-2004, we identified 1,981 MRSA case-patients and 19,779 matched control-patients. The odds ratios (ORs) and 95% confidence intervals (CIs) of MRSA diagnosis for patients who were prescribed 1, 2-3, or > or = 4 antimicrobial drugs were 1.57 (CI 1.36-1.80), 2.46 (CI 2.15-2.83), and 6.24 (CI 5.43-7.17), respectively. Risk for community-acquired MRSA increased with number of antimicrobial drug prescriptions, appeared to vary according to antimicrobial drug classes prescribed the previous year, and was highest for quinolones (OR 3.37, CI 2.80-4.09) and macrolides (OR 2.50, CI 2.14-2.91).

References

Oct 3, 1998·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·D L Monnet
Apr 23, 1999·Lancet·T Walley, A Mantgani
Oct 21, 1999·Journal of Public Health Medicine·R LawrensonR Farmer
Dec 6, 2001·The Journal of Antimicrobial Chemotherapy·R A Lawrenson, J W Logie
Jun 1, 2002·The Journal of Antimicrobial Chemotherapy·Eileen M Graffunder, Richard A Venezia
Jan 11, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Cassandra D SalgadoDavid P Calfee
Dec 11, 2003·JAMA : the Journal of the American Medical Association·Timothy S NaimiRuth Lynfield
Jan 14, 2004·Emerging Infectious Diseases·Stephen G WeberYehuda Carmeli
Feb 4, 2005·The New England Journal of Medicine·Sophia V KazakovaDaniel B Jernigan
Mar 29, 2005·Hospital Medicine·Mark H Wilcox
Apr 9, 2005·The New England Journal of Medicine·Scott K FridkinUNKNOWN Active Bacterial Core Surveillance Program of the Emerging Infections Program Network
Apr 28, 2005·The Lancet Infectious Diseases·Nicola ZetolaWilliam R Bishai
Jul 13, 2005·The Journal of Hospital Infection·D L MonnetN Frimodt-Møller
Sep 27, 2005·The Lancet Infectious Diseases·John M BoyceDidier Pittet
Feb 9, 2006·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Karl J Madaras-KellyDennis L Stevens
Feb 16, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Pierre CharbonneauUNKNOWN French Fluoroquinolone Free (3F) Study Group
Jul 1, 2006·Thorax·E M W van de GardeH G M Leufkens
Sep 27, 2006·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Sandra DialSamy Suissa
Oct 31, 2006·The American Journal of Medicine·Nancy F CrumKevin L Russell

❮ Previous
Next ❯

Citations

Aug 12, 2009·The Journal of Laryngology and Otology·I Brook
Apr 3, 2010·British Medical Bulletin·Fiona J Cooke, Nicholas M Brown
Mar 14, 2009·The Journal of Antimicrobial Chemotherapy·F Kate GouldUNKNOWN MRSA Working Party of the British Society for Antimicrobial Chemotherapy
Aug 25, 2012·Interdisciplinary Perspectives on Infectious Diseases·Saoraya Lueangarun, Amorn Leelarasamee
Dec 20, 2007·BMC Cardiovascular Disorders·Joseph A C DelaneySamy Suissa
Oct 30, 2009·Journal of the Formosan Medical Association = Taiwan Yi Zhi·Wen-Tsung Lo, Chih-Chien Wang
Feb 26, 2016·Journal of Clinical Orthopaedics and Trauma·Sanjay AgarwalaAnshul Sobti
Nov 11, 2008·Disease-a-month : DM·David K Byers, Catherine F Decker
Feb 9, 2010·Risk Analysis : an Official Publication of the Society for Risk Analysis·Jane HellerDominic J Mellor
Jun 19, 2008·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·J A Otter, G L French
Apr 12, 2012·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·K SkalskyM Paul
Mar 23, 2013·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·J M CisnerosUNKNOWN PRIOAM team
Mar 4, 2014·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·M BassettiM Wilcox
May 7, 2009·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·Y LongtinS Harbarth
Jul 28, 2016·BMC Health Services Research·Jessie O OyinlolaAntonis A Kousoulis
Mar 15, 2008·The Journal of Antimicrobial Chemotherapy·Dilip NathwaniUNKNOWN British Society for Antimicrobial Chemotherapy Working Party on Community-onset MRSA Infections
Jan 10, 2012·The Annals of Otology, Rhinology, and Laryngology·Itzhak Brook, Jeffrey N Hausfeld
Aug 19, 2011·Otolaryngology--head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery·Inessa FishmanJulie L Wei
Jun 4, 2008·Expert Opinion on Pharmacotherapy·Edina Avdic, Sara E Cosgrove
Jan 19, 2016·Current Opinion in Infectious Diseases·Cristina Vazquez Guillamet, Marin H Kollef
Sep 14, 2018·Clinical Microbiology Reviews·Sahreena Lakhundi, Kunyan Zhang
Oct 16, 2020·The Journal of Infectious Diseases·Kazuhiko IkeuchiHiroshi Yotsuyanagi
Jun 2, 2021·The Medical Clinics of North America·Renajd RrapiDaniela Kroshinsky
Mar 26, 2010·The Lancet Infectious Diseases·Jonathan A Otter, Gary L French

❮ Previous
Next ❯

Software Mentioned

SAS

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.